Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15404590 | 1.00 | MME (0.35) | MMEDPP4FASNATMPDE7A | |
| SCHEMBL22042454 | 0.91 | MME (0.32) | MMEDPP4 | |
| SCHEMBL22042599 | 0.91 | MME (0.32) | MMEDPP4 | |
| SCHEMBL22042408 | 0.89 | MME (0.31) | MME | |
| SCHEMBL14658519 | 0.83 | MME (0.46) | MMEFASNPDE7A | |
| SCHEMBL3715481 | 0.83 | MME (0.46) | MMEFASNPDE7A | |
| SCHEMBL7447161 | 0.83 | MME (0.50) | MMEDPP4FASNPDE7ATSHR | |
| SCHEMBL22042484 | 0.81 | MMP2 (0.33) | — | |
| SCHEMBL23826739 | 0.80 | CHRNB2 (0.32) | — | |
| SCHEMBL16240628 | 0.80 | CHRNB2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| EP-2684880-A1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8629133-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TPD52L2 | MME 4106/4885DPP4 2001/4885FASN 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.